Effect of fluoxetine on motor disorders induced by intranigral injection of 6-hydroxydopamine in rats

Pharmaceutical Sciences

Volumn 16, Issue 1, 2010, Pages 47-56

  Alireza, Mohajjel Nayebi ^a,b   Siyamak, Reyhani Rad ^c   Mahmoudi, Javad ^d   Samini, Morteza ^d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

6 OHDA; Fluoxetine; Intra nigral; Motor disorders; Rat

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; FLUOXETINE; OXIDOPAMINE; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BALANCE IMPAIRMENT; CATALEPSY; CLINICAL EVALUATION; DRUG EFFICACY; DRUG MECHANISM; MALE; MONOTHERAPY; NONHUMAN; PARKINSON DISEASE; RAT; ROTAROD TEST; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

EID: 77958533004     PISSN: 1735403X     EISSN: 23832886     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Scholtissen B., Verhey F.R.J. Steinbusch H.W.M., Leentjens A.F.G. Serotonergic mechanisms in Parkinson's Disease: opposing results from preclinical and clinical data, Journal of Neural Transmission, 2006, 113: 59-73. (Pubitemid 41828957)
2. Miyawaki E., Mean Y., Koller W.C. Serotonin, dopamine and motor effects in Parkinson's disease, Clin. Neuropharmacol., 1997,20: 300-310. (Pubitemid 27329732)
3. Chase T.N. Serotonergic mechanisms in Parkinson's disease, Arch. Neurol., 1972, (27): 354-356.
4. 2A receptors are increased in parkinson's disease neocortex, Ann. N.Y. Acad. Sci., 1998, 861: 288-289.
5. Pires J.G., Bonikovski V., Futuro-Neto H.A. Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice, Braz. Med. Biol. Res., 2005, 38: 1867-1872. (Pubitemid 43078616)
6. De Deurwaerdere P., Navailles S., Berg K.A., Clark W.P., Spampinato U. Constitutive activity of the serotonin 2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens, J. Neurosci., 2004, 24: 3235-3241. (Pubitemid 38451889)
7. Benloucif S., Keegan M.J., Galloway M.P., Serotonin-facilated dopamine release in vivo: pharmacological characterization, J. Pharmacol. Exp. Ther., 1993, 265:373-377. (Pubitemid 23320984)
8. Matsubara K., Shimizu K., Suno M., Ogawa K., Awaya T., Yamada T., Noda T., Satomi M., Ohtaki K., Chiba K., Tasaki Y., Shiono H. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res., 2006, 1112: 126-133. (Pubitemid 44344618)
9. 1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat, Neuropharmacology, 2008, 55: 1321-1328.
10. 1B serotonin receptors in adult rat brain, J. Comp. Neurol., 2000, 417: 181-194.
11. 1A agonists with potential anxiolytic properties, J. Pharmacol. Exp. Ther., 1988, 246: 745-752.
12. 1A receptor agonist, potentiated S(-)- sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum, J. Pharmacol. Exp. Ther., 1999, 291: 1227-1232.
13. 1A receptors in rat. Pharmacological Reports, 2010, 62(2): (In press).
14. Hamm R.J., Pike B.R., O'Dell D.M., Lyeth B.G., Jenkins L.W. The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury, J. Neurotrauma., 1994, 11: 187-196.
15. Nayebi A.M., Nazemiyeh H., Omidbakhsh R., Çobanoglu S. Analgesic effect of the methanol extract of Erica arborea (L.) in mice using formalin test. Daru, 2008, 16: 229-232.
16. Wang S., Hu L.F., Yang Y., Ding J.H., HU G. Studies of ATP-seneitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: Implications for treating Parkinson's disease? Neuropharmacology, 2005, 48: 984-992.
17. Eskow K.L., Gupta V., Alam S., Park J.Y., Bishop C. The partial 5-HT1A agonist buspirone reduces the expression and development of 1-DOPA-induced dyskinesia in rats and improves 1-DOPA efficacy, Pharmacol. Biochem. Behav., 2007, 87: 306-314. (Pubitemid 47101876)
18. 1B receptor agonists in the rat Parkinson model, Exp. Neurol., 2009, 219: 298-307.
19. Pinna G., Costa E., Guidotti A. Fluoxetine and norfluoxetine stereospecifically facilitate pentobarbital sedation by increasing neurosteroids, Proc. Natl. Acad. Sci. U S A, 2004, 101: 6222-6225. (Pubitemid 38520555)
20. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res., 2007, 179: 76-89.
21. Forjaz M.J., Rodriguez-Blázquez C., Martinez-Martin P. Rasch analysis of the hospital anxiety and depression scale in Parkinson's disease, Mov. Disord., 2008, 24: 525-531.
22. Schrag A, Barone P., Brown R.G., Leentjens A.F.G, McDonald W.M., Starkstein S., Weintraub D., Poewe W., Rascol O., Sampaio C., Stebbins G.T., Goetz C.G. Depression Rating Scales in Parkinson's Disease: Critique and Recommendations, Mov. Disord., 2007, 22: 1077-1092.